MoonLake Immunotherapeutics
MLTX
125 hedge funds and large institutions have $3.53B invested in MoonLake Immunotherapeutics in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 51 increasing their positions, 33 reducing their positions, and 28 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 33
32% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 28
10% more capital invested
Capital invested by funds: $3.21B → $3.53B (+$322M)
6% more funds holding
Funds holding: 118 → 125 (+7)
6.21% less ownership
Funds ownership: 105.3% → 99.09% (-6.2%)
16% less call options, than puts
Call options by funds: $39.7M | Put options by funds: $47.3M
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$53.6M |
| 2 |
Holocene Advisors
New York
|
+$44.1M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$29.9M |
| 4 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$29M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$44.3M |
| 2 |
RI
RTW Investments
New York
|
-$28.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$22M |
| 4 |
BlackRock
New York
|
-$18.9M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$14.4M |
MLTX Hedge Fund Activity: Q4 2023 in Review
125 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2023, worth a combined $3.53B — up 10% from $3.21B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new MLTX positions and 28 closed out — a net gain of 9 holders — while 51 added to existing stakes and 33 trimmed.
The largest buyer was Darwin Global Management, opening a new position worth an estimated $53.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $44.3M sold.
- 125 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2023, up from 118 in Q3 2023.
- Funds reported $3.53B of MoonLake Immunotherapeutics stock for Q4 2023, up 10% quarter-over-quarter.
- 37 funds opened new MoonLake Immunotherapeutics positions in Q4 2023 and 28 closed out, a net change of +9 holders.
- The largest MoonLake Immunotherapeutics buyer in Q4 2023 was Darwin Global Management, an estimated $53.6M added.
- The largest MoonLake Immunotherapeutics seller in Q4 2023 was Avidity Partners Management, an estimated $44.3M sold.
Based on aggregated 13F filings for Q4 2023.